Last reviewed · How we verify
NCT04686487: SELECT
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
NA trial testing stereotactic ablative radiotherapy in Hypertrophic Obstructive Cardiomyopathy in 5 participants. Completed in 1 November 2022.
30 April 2022
Quick facts
| Lead sponsor | Second Xiangya Hospital of Central South University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 12 January 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 1 November 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- stereotactic ablative radiotherapy
Conditions studied
- Hypertrophic Obstructive Cardiomyopathy — all drugs for Hypertrophic Obstructive Cardiomyopathy →
Sponsor
Second Xiangya Hospital of Central South University
Who can join
18 and older, any sex, with Hypertrophic Obstructive Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing risk of sudden cardiac death, heart failure, and atrial fibrillation. Surgical septal myectomy and alcohol septal ablation are two invasive therapies for drug-refractory symptomatic patients with HOCM. Unfortunately, some patients may be unsuitable for both the two procedures. Recently, stereotactic ablative radiotherapy, usually used for the treatment of tumours, was confirmed to be feasible, safe and effective in destroying abnormal tissue in heart by targeting high energy heavy ion beams at a specific area of the body precisely. In this study we will determine whether radiation ablation, can be used to destroy the thick heart muscle at the point of obstruction safely and effectively.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Septal radioablation therapy for patients with hypertrophic obstructive cardiomyopathy: first-in-human study.
Li X, Zhu Z, Liu J, Gao Y, et al · · 2023 · cited 6× · PMID 37503357 · DOI 10.1093/ehjopen/oead052
Verify or expand the search:
- PubMed search for NCT04686487
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of stereotactic ablative radiotherapy
Trials testing the same drug.
- NCT06084338 — Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc · Phase 2 · recruiting
- NCT05265663 — Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients · NA · unknown
Other recruiting trials for Hypertrophic Obstructive Cardiomyopathy
Currently open trials in the same condition.
- NCT05332691 — Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy · NA · recruiting
- NCT05257772 — Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM) · NA · active not recruiting
Other Second Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07278947 — ACT-based Parenting Program for Caregivers of Children With Hearing Loss Post-cochlear: A Pilot Randomised Controlled Tr · NA · not yet recruiting
- NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07343154 — Multimodal Brain Function in Migraine Patients With Patent Foramen Ovale · not yet recruiting
- NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04686487 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Xiangya Hospital of Central South University
- Last refreshed: 30 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04686487.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing